Healthspan Capital

Reservoir Neuroscience, Inc. is a biopharmaceutical company focused on developing innovative therapeutics aimed at repairing the blood-brain barrier and restoring vascular function in the brain. Founded in 2019 and based in Emeryville, California, the company targets neurological disorders, including Alzheimer's disease, by addressing dysfunctional blood vessels in the brain. Its therapeutics are designed to improve cognitive function and enhance disease outcomes for patients suffering from age-related cognitive impairment and other neurological conditions.

KetoSwiss is a Swiss-based biotech startup focused on developing innovative nutraceuticals aimed at addressing metabolic dysfunction in neurological diseases, particularly higher-frequency migraines and potentially Alzheimer's disease. The company is dedicated to creating a novel medical food that enhances brain energetics by providing ketone bodies as an alternative fuel source when glucose metabolism is impaired. Located in the Technologie Park Basel, KetoSwiss operates within a vibrant community of academic research and life sciences innovation, positioning itself at the forefront of preventive therapies for neurological conditions. Through rigorous clinical testing, KetoSwiss seeks to offer effective dietary solutions to improve the quality of life for patients affected by these conditions.

Repair Biotechnologies, Inc. is a biotechnology company founded in 2018 and based in Syracuse, New York. The company focuses on developing innovative therapies aimed at reversing the progression of age-related conditions such as immunosenescence and atherosclerosis. Utilizing a cholesterol-degrading platform, Repair Biotechnologies creates treatments that address conditions driven by excess or modified cholesterol, including atherosclerosis and familial hypercholesterolemia. Their approach centers on gene therapy and recombinant protein strategies, designed to be safe and well-tolerated, allowing patients to target the underlying causes of diseases associated with cholesterol accumulation.

Deciduous Therapeutics is a biotechnology company focused on developing innovative immune-modulatory therapies aimed at addressing age-related diseases. The company specializes in creating novel molecules that activate the body's natural immune surveillance mechanisms to selectively eliminate senescent cells, which are associated with various age-related conditions. Led by Anil Bhushan, a professor at UCSF, and Robin Mansukhani, an experienced biotech entrepreneur, Deciduous Therapeutics is dedicated to promoting a healthier lifespan through its pioneering approach to therapeutics in the aging sector.

KetoSwiss is a Swiss-based biotech startup focused on developing innovative nutraceuticals aimed at addressing metabolic dysfunction in neurological diseases, particularly higher-frequency migraines and potentially Alzheimer's disease. The company is dedicated to creating a novel medical food that enhances brain energetics by providing ketone bodies as an alternative fuel source when glucose metabolism is impaired. Located in the Technologie Park Basel, KetoSwiss operates within a vibrant community of academic research and life sciences innovation, positioning itself at the forefront of preventive therapies for neurological conditions. Through rigorous clinical testing, KetoSwiss seeks to offer effective dietary solutions to improve the quality of life for patients affected by these conditions.

Samsara Therapeutics, founded in 2018 with operations across Europe and San Diego, is a biopharmaceutical company dedicated to discovering and developing therapeutics for age-related diseases and unmet medical needs. Its proprietary platform focuses on identifying and validating compounds that extend healthy lifespan by targeting fundamental aging processes such as proteostasis and autophagy. The company aims to create novel treatments for rare genetic and neurodegenerative diseases through its pipeline, which involves compound identification, chemical optimization, and in vivo validation across various species.

Immunis is a private biotechnology company focused on addressing age and disease-related immune decline through innovative stem cell-derived therapies. The company specializes in utilizing human stem cells to create specific populations of cells that secrete therapeutic factors. This approach aims to enable healthcare professionals to enhance immune system development, modulation, and overall health in patients. By harnessing the potential of stem cell technology, Immunis seeks to offer novel treatment options that can improve immune function and combat the effects of aging and various diseases.

Metanoia Bio is a pre-clinical Biotech start-up spun out of the University of California Los Angeles (UCLA).

ImmuneBridge develops allogeneic immunotherapies for cancer treatment. Its key innovation involves creating immune stem cells from cord blood, providing a fresh, adaptable, reliable, and abundant cellular source for immunotherapies.

Shift Bioscience is a biotechnology company focused on combating the diseases associated with aging through innovative cellular reprogramming techniques. The company has developed a high-throughput, high-accuracy aging biomarker, which is integrated into AI-driven simulations to identify safer gene factors for rejuvenation. By leveraging deep learning technology, Shift tests extensive gene combinations to discover potential drug candidates that can reverse aging and age-related diseases. The company's goal is to create a single family of drugs capable of addressing multiple age-related conditions, ultimately allowing for improved health and longevity through simple prescriptions.

Weatherwax Bio develops the next generation of induced-proximity medicines. The company was founded in 2019 and is based in San Francisco, California.

Reservoir Neuroscience, Inc. is a biopharmaceutical company focused on developing innovative therapeutics aimed at repairing the blood-brain barrier and restoring vascular function in the brain. Founded in 2019 and based in Emeryville, California, the company targets neurological disorders, including Alzheimer's disease, by addressing dysfunctional blood vessels in the brain. Its therapeutics are designed to improve cognitive function and enhance disease outcomes for patients suffering from age-related cognitive impairment and other neurological conditions.